Mount Sinai launches initiative to accelerate precision immunology treatments

Mount Sinai has launched the Precision Immunology and Experimental Medicine Trial Organization (PrIME Trials), a new initiative within the Marc and Jennifer Lipschultz Precision Immunology Institute at the Icahn School of Medicine at Mount Sinai. Bringing together scientific and clinical expertise, PrIME Trials aims to accelerate the development of therapies that target the underlying causes of inflammatory and autoimmune diseases, with the potential to achieve more durable responses and lasting remission.

PrIME Trials represents a fundamental shift in how we approach immune-mediated diseases. Many diseases traditionally managed by separate specialties share common immune mechanisms. By bringing our expertise together, we can accelerate the development of promising therapies. One of the biggest barriers to new treatments is the time it takes to initiate clinical trials. Our goal is to reduce bureaucracy, streamline processes, and bring innovative therapies to patients faster."

Miriam Merad, MD, PhD, Director of the Marc and Jennifer Lipschultz Precision Immunology Institute

PrIME Trials provides academic and industry partners with a coordinated pathway for developing and conducting early-phase clinical trials, from study design and activation through patient enrollment and scientific analysis. The program supports the evaluation of therapies across diseases that share common immune mechanisms. Through integration with Mount Sinai's OCCAM Immune research platform, investigators can also study how individual patients' immune systems respond to treatment, helping explain why therapies succeed or fail and informing future treatment development.

PrIME Trials brings together the scientific leadership of Dr. Merad, the medical leadership of Louis J. Cohen, MD, and clinical research operations leadership from Rosemarie Gagliardi.

A central component of PrIME Trials is FASTrack (Facilitated Activation and Start Up of Trials), a coordinated process designed to initiate selected complex clinical trials in 60 days or less. By aligning scientific, regulatory, contracting, financial, and operational activities, FASTrack aims to shorten start-up timelines while maintaining rigorous standards for scientific quality and patient safety.

PrIME Trials' first major clinical trial, a Sanofi-sponsored, first-in-human study of an investigational in vivo CAR-T therapy for immune-mediated conditions, was initiated in less than 60 days. The trial is led by Margrit Wiesendanger, MD, PhD, Associate Professor of Medicine (Rheumatology), with Jacques Azzi, MD, Assistant Professor of Medicine (Hematology), as co-investigator. This rapid activation of this trial was also due to the collaboration between PrIME Trials, Sanofi and the CTrials program offered by BRANY (Biomedical Research Alliance of New York).

"The launch of PrIME Trials reflects Mount Sinai's commitment to building the infrastructure needed to translate scientific discoveries into advances in patient care as quickly and efficiently as possible while ensuring patient safety," says Eric J. Nestler, MD, PhD, Anne and Joel Ehrenkranz Dean of the Icahn School of Medicine at Mount Sinai, and Executive Vice President and Chief Scientific Officer of the Mount Sinai Health System. "By combining expertise in immunology with centralized clinical research capabilities and innovative approaches to trial activation, we are creating an environment that supports scientific collaboration, strengthens industry partnerships, and accelerates the development of promising treatments."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Can microplastics get under your skin? What everyday exposure could mean for your health